Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced its sponsorship of the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, in Louisville, KY. The company will showcase its KetoAir™ breathalyzer device, designed to monitor ketosis through breath analysis. Conference attendees will have the opportunity to see live demonstrations and purchase the device along with related accessories on-site.
The KetoAir™ breathalyzer is a handheld device specifically engineered for ketogenic health management. It measures breath acetone concentration (BrAce) to assess ketosis status without invasive blood tests. The device is FDA-registered and accessible via both Apple App Store and Google Play Store. Avalon's subsidiary, Q&A Distribution , holds exclusive distributorship rights for KetoAir™ in North America, South America, EU, and UK.
Avalon GloboCare Corp. (NASDAQ: ALBT) ha annunciato il suo patrocinio per la Conferenza Keto Pa-LOU-za 2024, che si terrà dall'11 al 13 ottobre 2024 a Louisville, KY. L'azienda presenterà il suo dispositivo di analisi del respiro KetoAir™, progettato per monitorare la chetosi attraverso l'analisi dell'alito. I partecipanti alla conferenza avranno l'opportunità di vedere dimostrazioni dal vivo e acquistare il dispositivo insieme agli accessori correlati direttamente in loco.
Il dispositivo di analisi del respiro KetoAir™ è un dispositivo portatile specificamente progettato per la gestione della salute chetogenica. Misura la concentrazione di acetone nel respiro (BrAce) per valutare lo stato di chetosi senza test del sangue invasivi. Il dispositivo è registrato presso la FDA ed è accessibile sia tramite Apple App Store che Google Play Store. La controllata di Avalon, Q&A Distribution, detiene i diritti di distribuzione esclusivi per KetoAir™ in Nord America, Sud America, UE e Regno Unito.
Avalon GloboCare Corp. (NASDAQ: ALBT) ha anunciado su patrocinio para la Conferencia Keto Pa-LOU-za 2024, que se llevará a cabo del 11 al 13 de octubre de 2024 en Louisville, KY. La empresa presentará su dispositivo de analizador de aliento KetoAir™, diseñado para monitorear la cetosis a través del análisis del aliento. Los asistentes a la conferencia tendrán la oportunidad de ver demostraciones en vivo y comprar el dispositivo junto con accesorios relacionados en el lugar.
El analizador de aliento KetoAir™ es un dispositivo portátil específicamente diseñado para la gestión de la salud cetogénica. Mide la concentración de acetona en el aliento (BrAce) para evaluar el estado de cetosis sin pruebas de sangre invasivas. El dispositivo está registrado en la FDA y es accesible tanto a través de Apple App Store como de Google Play Store. La subsidiaria de Avalon, Q&A Distribution, tiene derechos de distribución exclusivos para KetoAir™ en América del Norte, América del Sur, EU y Reino Unido.
Avalon GloboCare Corp. (NASDAQ: ALBT)는 2024년 10월 11일부터 13일까지 켄터키주 루이빌에서 열리는 Keto Pa-LOU-za 2024 컨퍼런스의 후원을 발표했습니다. 회사는 KetoAir™ 호흡 분석기를 선보일 예정이며, 이는 호흡 분석을 통해 케토시스를 모니터링하도록 설계되었습니다. 컨퍼런스 참석자들은 라이브 시연을 보고 관련 액세서리와 함께 현장에서 장치를 구매할 기회를 갖게 됩니다.
KetoAir™ 호흡 분석기는 케토제닉 건강 관리를 위해 특별히 설계된 휴대용 장치입니다. 이 장치는 호흡 내 아세톤 농도(BrAce)를 측정하여 비침습적인 혈액 검사 없이 케토시스 상태를 평가합니다. 이 장치는 FDA에 등록되어 있으며 Apple App Store 및 Google Play Store를 통해 접근할 수 있습니다. 아발론의 자회사인 Q&A Distribution은 북미, 남미, 유럽 연합 및 영국에서 KetoAir™의 독점 유통권을 보유하고 있습니다.
Avalon GloboCare Corp. (NASDAQ: ALBT) a annoncé son parrainage de la conférence Keto Pa-LOU-za 2024, qui se déroulera du 11 au 13 octobre 2024 à Louisville, KY. L'entreprise présentera son dispositif d'analyse de souffle KetoAir™, conçu pour surveiller la cétose grâce à l'analyse de l'haleine. Les participants à la conférence auront l'occasion de voir des démonstrations en direct et d'acheter l'appareil ainsi que des accessoires connexes sur place.
Le dispositif d'analyse de souffle KetoAir™ est un appareil portable spécifiquement conçu pour la gestion de la santé cétogène. Il mesure la concentration d'acétone dans l'haleine (BrAce) pour évaluer l'état de cétose sans tests sanguins invasifs. L'appareil est enregistré auprès de la FDA et est accessible à la fois via l'Apple App Store et le Google Play Store. La filiale d'Avalon, Q&A Distribution, détient les droits de distribution exclusifs pour KetoAir™ en Amérique du Nord, en Amérique du Sud, dans l'UE et au Royaume-Uni.
Avalon GloboCare Corp. (NASDAQ: ALBT) hat seine Sponsoring für die Keto Pa-LOU-za 2024 Konferenz angekündigt, die vom 11. bis 13. Oktober 2024 in Louisville, KY, stattfinden wird. Das Unternehmen wird sein KetoAir™ Atemanalysator präsentieren, das zur Überwachung der Ketose durch Atemanalyse entwickelt wurde. Die Teilnehmer der Konferenz haben die Möglichkeit, Live-Demonstrationen zu sehen und das Gerät zusammen mit verwandtem Zubehör vor Ort zu kaufen.
Der KetoAir™ Atemanalysator ist ein tragbares Gerät, das speziell für das Management der ketogenen Gesundheit entwickelt wurde. Es misst die Acetonkonzentration im Atem (BrAce), um den Ketose-Status ohne invasive Blutuntersuchungen zu bewerten. Das Gerät ist von der FDA registriert und sowohl im Apple App Store als auch im Google Play Store verfügbar. Avalons Tochtergesellschaft, Q&A Distribution, hält die exklusiven Vertriebsrechte für KetoAir™ in Nordamerika, Südamerika, der EU und dem Vereinigten Königreich.
- Sponsorship of Keto Pa-LOU-za 2024 Conference provides exposure to target market
- Opportunity for direct sales of KetoAir™ device and accessories at the conference
- KetoAir™ offers non-invasive ketosis monitoring, potentially appealing to health-conscious consumers
- FDA registration for KetoAir™ (registration number: 3026284320)
- Exclusive distributorship rights for KetoAir™ in major markets
- None.
Insights
The KetoAir™ breathalyzer represents a significant advancement in non-invasive ketosis monitoring for the growing ketogenic diet market. Its FDA registration (number 3026284320) lends credibility to the device's medical application. The nano-sensor technology for measuring breath acetone concentration (BrAce) offers a convenient alternative to blood tests, potentially increasing user adherence to ketogenic diets.
However, the impact on Avalon GloboCare's financials remains uncertain. While sponsoring the Keto Pa-LOU-za 2024 Conference provides exposure, it's unclear how this will translate to sales or market share. The exclusive distribution rights for KetoAir™ in major markets could be a significant revenue driver if the product gains traction, but adoption rates and pricing strategies are not disclosed.
Investors should monitor sales figures and user feedback post-conference to gauge the potential impact on Avalon's bottom line. The integration with mobile apps adds value, but competition in the health tech space is fierce. Long-term success will depend on clinical validation, user experience and effective marketing to both consumers and healthcare professionals.
KetoAir and its related accessories will be available for purchase at the conference
FREEHOLD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced its participation as an event sponsor at the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, at the Galt House Hotel in Louisville, KY.
Avalon will use the event to showcase the KetoAir™ breathalyzer device, a handheld device designed to monitor ketosis via breath analysis. Conference attendees will have the opportunity to see live demonstrations of the device and purchase it, along with related accessories, directly on-site.
“We are excited to partner with the Keto Pa-LOU-za 2024 Conference and introduce the KetoAir™ device to a passionate and health-conscious community. This event provides an ideal platform to connect with individuals and key influencers who are committed to the ketogenic lifestyle and to highlight the innovative capabilities of KetoAir™ in supporting their health journey,” said David Jin, M.D., Ph.D., CEO of Avalon.
The Keto Pa-LOU-za Conference gathers keto enthusiasts from across the country to share tips, insights, and resources for maintaining a ketogenic lifestyle. Avalon’s KetoAir™ breathalyzer offers a user-friendly way to track ketosis in real-time without invasive blood tests.
KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). KetoAir™ measures an individual's breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store. The Company, through its subsidiary Q&A Distribution LLC, has exclusive distributorship rights for the KetoAir™ in North America, South America, EU, and UK.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is Avalon GloboCare showcasing at the Keto Pa-LOU-za 2024 Conference?
When and where is the Keto Pa-LOU-za 2024 Conference taking place?
What does the KetoAir™ breathalyzer measure?
Where can consumers access the KetoAir™ app?
What are Avalon GloboCare's (ALBT) distribution rights for KetoAir™?
